louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06129708: Effect of Aquatic Exercise Versus Aerobic Exercise on Primary Dysmenorrhea and Quality of Life in Adolescent Females
Official title: Effect of Aquatic Exercise Versus Aerobic Exercise on Primary Dysmenorrhea and Quality of Life in Adolescent Females: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dysmenorrhea Primary
Keywords: Primary Dysmenorrhea
Adolescent Females
Aquatic Exercise
Aerobic Exercise
Pressure Pain Threshold
Quality of Life
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-11-13
Enrollment: 60
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was conducted to determine the difference between impact of aerobic and aquatic exercise on primary dysmenorrhea and quality of life in adolescent girls.

Detailed description: Dysmenorrhea manifests as painful menstrual flow it occurs in two forms primary and secondary. Primary and secondary dysmenorrhea is painful menstruation occur without any gynecological disease it was conducted that prevalence of dysmenorrhea 74.6% and it was significantly more frequent in students from rural residence (Shaimaa et al., 2018).

There is only one previous study investigate effect of aquatic exercise on primary dysmenorrhea (Rezvani et al., 2013). There are several previous studies investigate effect of aerobic ex , however non of the previous studies compared between effect of aerobic and aquatic exercise on primary dysmenorrhea and quality of life of adolescent girls .Therefore this study was the first one which aimed to investigate the difference between effect of aerobic and aquatic exercise on primary dysmenorrhea and quality of life in adolescent girls.

Eligibility criteria: Inclusion Criteria:

* Healthy, nonsmoking, virginal girls having moderate to severe primary dysmenorrhea (score on pain rating scale \> 3).
* Their ages ranged from 14 to 20 years
* Their body mass index (BMI) ranged from 18 to 25 kg/m2.
* They haven't practice any sports at least one year

Exclusion Criteria:

* Any musculoskeletal disorder.
* Cardio-respiratory disease.
* Diabetes, hypertension, or anemia.
* Adolescent girls who have utilized hormonal treatment in the six months prior to study commencement.
* currently undergoing pharmacological therapy for menstrual pain management

Primary outcomes:
measure: Assessment of dysmenorrhea severity
timeFrame: 12 weeks
measure: Measurement of pain intensity
timeFrame: 12 weeks
measure: Assessment of pressure pain threshold (PPT)
timeFrame: 12 weeks
measure: Assessment of health related quality of life
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo University
Study officials:
affiliation: Department of Physical Therapy for Woman's Health, Faculty of physical therapy, Cairo University, Giza, Egypt.
name: Sohier M. Elkosery, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT03060408: Comparison of Fluid Requirements in Pancreatectomy: Laparotomy vs. Laparoscopy
Official title: Comparison of Intraoperative Basal Fluid Requirements in Distal Pancreatectomy - Laparotomy vs. Laparoscopy: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatectomy
Fluid Therapy
Laparoscopy
Keywords: Fluid Therapy
Laparoscopy
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 304
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: indication of distal pancreatectomy

Brief summary: In this retrospective cohort study, the investigators reviewed and analyzed the electronic medical records of consecutive patients who underwent distal pancreatectomy either via laparotomy or laparoscopy. Intraoperative fluid administration amount, postoperative complications, length of hospital stay, and readmission rate were evaluated. The total fluid amounts were calculated using the sum of colloids multiplied by 1.5 or 2.0 and crystalloids.

Detailed description: There has been recent progress in intraoperative fluid therapy. However, little is known about intraoperative fluid therapy in laparoscopic surgery. The purpose of this study is to determine whether there are differences in the basal fluid requirements during surgery between laparotomy and laparoscopic distal pancreatectomy. This study analyzed the records between June 2006 and March 2016. And 253 patients who underwent distal pancreatectomy via either laparotomy (73 patients) or laparoscopy (180 patients). This study was based on a retrospective review and analysis of the electronic medical records. The volume of intraoperative fluid administered, postoperative complications, length of hospital stay, and readmission rate were evaluated. The total volume of fluids was calculated as the sum of the volume of crystalloid plus the volume of colloid multiplied by 1.5 or 2.0.

Eligibility criteria: Inclusion Criteria:

* indication of distal pancreatectomy

Exclusion Criteria:

* transfusion
* ASA physical status over 4
* co-operate other surgery

Primary outcomes:
measure: intraoperatively administered fluid amounts
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04047108: pedCAPNETZ - Community Acquired Pneumonia (CAP) in Childhood and Adolescence
Official title: pedCAPNETZ - Development and Detailed Characterization of a Cohort for Community Acquired Pneumonia (CAP) in Childhood and Adolescence
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Community-acquired Pneumonia
Lead sponsor: Hannover Medical School
Sponsor class: OTHER
First posted: 2019-08-06
Enrollment: 1000
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: CAP patients age \< 18

Brief summary: Establishment of a study network and patient cohort for pediatric CAP

Detailed description: The aim of the project is the development of a large pediatric CAP patient cohort based on the established pedCAPNETZ pilot cohort. The main objective is to improve knowledge on etiology, epidemiology, diagnosis and management of pediatric CAP in a developed country. pedCAPNETZ will enable the systematic and detailed characterization of pediatric CAP cases on an epidemiological, clinical and biological level.

Eligibility criteria: Inclusion Criteria:

* age \< 18
* symptoms of an acute lower respiratory tract infection with radiological confirmed pneumonia via ultrasound or chest x-ray

Exclusion Criteria:

* hospitalization for any reason within the last 28 days
* congenital or acquired immunodeficiency
* concomitant respiratory disease with impaired mucociliary clearance such as cystic fibrosis, primary ciliary dyskinesia, tracheostomy or other severe lung disease including pulmonary tuberculosis, malignancy, and cytostatic therapy during past 28 days or neutropenia (\< 1000/µl) or relevant immunosuppressive treatment

Primary outcomes:
measure: Number of patients with pediatric community acquired pneumonia (pedCAP) across all different levels of health care
timeFrame: 5 years
measure: Prevalence of pedCAP and etiologies (composite outcome measures) across all different levels of health care
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
Study officials:
References:
Clinical trial NCT01453608: A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Official title: A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Iron Deficiency
Chronic Heart Failure
Lead sponsor: Vifor Pharma
Sponsor class: INDUSTRY
Collaborators: name: ICON Clinical Research
First posted: 2011-10-18
Enrollment: 304
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine, relative to placebo, the effect of iron repletion therapy using intravenous (IV) ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency.


Eligibility criteria: Inclusion Criteria:

* Iron deficient subjects with stable chronic heart failure (CHF) (NYHA II-III) on optimal background therapy for CHF
* Reduced left ventricular ejection fraction
* Capable of completing 6 minute walk test
* At least 18 years of age and with written informed consent prior to any study specific procedures

Exclusion Criteria:

* Erythropoietin stimulating agent (ESA) use, IV iron therapy and/or blood transfusion in previous 6 weeks prior to randomisation
* Exercise training program(s) in the 3 months prior to screening or planned in the next 6 months
* Chronic liver disease and/or elevated liver enzymes
* Vitamin B12 and/or serum folate deficiency
* Subject is not using adequate contraceptive precautions during the study
* Body weight ≤ 35 kg
* No other significant cardiac or general disorders that would compromise the ability to give informed consent and/or comply with study procedures

Primary outcomes:
measure: Change in six minute walk test from baseline to week 24
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Wroclaw
country: Poland
facility: Clinical Military Hospital
city: Ryazan
country: Russian Federation
facility: State Educational Institution of Higer Professional Education
Study officials:
affiliation: Cardiology Department - Centre for Heart Disease - Clinical Military Hospital
name: Piotr Ponikowski, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31.
Clinical trial NCT00140608: Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Chronic Sinusitis
Keywords: sinus
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2005-09-01
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate if the space occupying effect of Seprapack will lead to a reduction in post operative adhesions and more healing of the sinus cavity when compared to the use of no packing material.


Eligibility criteria: Inclusion Criteria:

* at least 18 years of age
* requiring bilateral endoscopic ethmoidectomy (anterior or posterior)
* intact middle turbinates
* willing to return for all follow-up visits
* signed written informed consent

Exclusion Criteria:

* patients with craniofacial abnormalities (e.g. cleft palate)
* patients without intact middle turbinates
* patients on long-term oral steroids or other chemotherapeutic agents that might delay healing. Short-term pulse steroid therapy and topical steroids are acceptable
* patients with inflammatory conditions, other than chronic sinusitis or nasal polyposis, including but not limited to sarcoidosis, rhinitis, ozena, Wegner's granulomatosis, nasal malignancy, recreational drug abuse
* patients with cystic fibrosis
* women that are pregnant or women of childbearing age potential who are not practicing an acceptable method of birth control
* patients with bleeding disorders or who are receiving anticoagulants
* patients that may require a Lothrop procedure

Primary outcomes:
measure: reduction in post-operative scarring when compared to use of no sinus packing
Secondary outcomes:
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: North Carolina
city: Cincinnati
country: United States
facility: University of Cincinnati College of Medicine
state: Ohio
city: Memphis
country: United States
facility: UT Health Science Center
state: Tennessee
Study officials:
affiliation: Genzyme, a Sanofi Company
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT05765708: The Effect of Motor Imagery and Action Observation on Motor Skill Acquisition
Official title: The Effect of Motor Imagery and Action Observation on Motor Skill Acquisition in Healthy Adults
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Lead sponsor: Istanbul Medeniyet University
Sponsor class: OTHER
Collaborators: name: Istinye University
name: Ufuk University
First posted: 2023-03-13
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this study is to investigate the effects of Motor Imagery and Action Observation on Motor Skill Acquisition in healthy adults.


Eligibility criteria: Inclusion Criteria:

* Right hand dominance

Exclusion Criteria:

* Individuals with neurological, orthopedic, or rheumatological disease (for example: stroke, essential tremor, tennis player, trigger finger, rheumatoid arthritis, etc.)
* Severe cognitive problems

Primary outcomes:
measure: Finger Tapping Task
timeFrame: 5 minutes
Secondary outcomes:
measure: Movement Imagery Questionnaire-3
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medeniyet University
Study officials:
References:
Clinical trial NCT04645108: Coached or Non-Coached Weight Loss Intervention
Official title: Randomized, Parallel Trial of Overweight Men and Women Using a Coached or Non-Coached Weight Loss Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Behavior, Health
Behavior, Eating
Weight Loss
Overweight and Obesity
Self Efficacy
Lead sponsor: Noom Inc.
Sponsor class: INDUSTRY
First posted: 2020-11-27
Enrollment: 246
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effect of one-on-one coaching in the Noom Healthy Weight Program, a digital behavior change, weight loss intervention, compared to the same program with no coaching, as well as influential factors.


Eligibility criteria: Inclusion Criteria:

* Able to understand and provide informed consent
* 18-65 years old
* Self-report of good health (physical and mental)
* Not diagnosed with diabetes
* Overweight or obesity (BMI ≥ 27)
* Able to meet our criteria of adherence to the program (at least 1 engagement per week on one of the following: logged exercise, logged meals, steps, weigh-ins, coach messages, read articles, and days with at least one weigh-in.) For females
* Not 6 months postpartum
* Not planning to become pregnant in the next 5 months.

Exclusion Criteria:

* Inability or unwillingness of a participant to give written informed consent
* Currently pregnant or ≤ 6 months postpartum
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the quality of the data E.g., evidence of an eating disorder, major chronic condition

Primary outcomes:
measure: Weight
timeFrame: 4 months
measure: Self reported in app engagement measures
timeFrame: 4 months
Secondary outcomes:
measure: Quality of Life Via SF-12
timeFrame: 4 months
measure: Eating Behavior via the Dutch Eating Behavior Questionnaire
timeFrame: 4 months
measure: Resilience via Devereux Adult Resilience Survey
timeFrame: 4 months
measure: Self Efficacy via General Self-Efficacy Scale
timeFrame: 4 months
measure: Linguistic Features via Linguistic Inquiry Word Count (LIWC)
timeFrame: 16 weeks
Other outcomes:
Locations:
city: New York
country: United States
facility: Noom, Inc
state: New York
Study officials:
References:
Clinical trial NCT02959008: Continous Assessment of Cerebral Autoregulation With Near-infrared Spectroscopy
Official title: Continous Assessment of Cerebral Autoregulation With Near-infrared Spectroscopy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cerebral Blood Flow
Cerebral Perfusion Pressure
Lead sponsor: Beijing Electric Power Hospital
Sponsor class: OTHER
First posted: 2016-11-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. adult
2. health people
3. people with hypertension

Brief summary: Cerebral autoregulation can be explained by a tight coupling between oxygen supply and demand of the brain, and is essential to maintain a constant cerebral blood flow (CBF) in the context of changes in cerebral perfusion pressure. In this study, investigators use Near-infrared spectroscopy (NIRS) to monitor cerebral autoregulation.

Detailed description: Near-infrared spectroscopy (NIRS) is a noninvasive technology that real-time monitors cerebral tissue oxygenation index (TOI). Investigators use Near-infrared spectroscopy (NIRS) to monitor cerebral autoregulation of hypertensive participants and non-hypertensive participants.

Eligibility criteria: Inclusion Criteria:

* health people, or people with hypertension

Exclusion Criteria:

* diabetes, anemia, liver disease, kidney disease.

Primary outcomes:
measure: range of cerebral autoregulation
timeFrame: 30min
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Beijing Electric Power Hospital
name: Xiaohong Wu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06938308: Comparison Between the I-gel and Protector Supraglottic Airway Devices
Official title: Comparison Between the I-gel and Protector Supraglottic Airway Devices in Patients Under General Anesthesia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Airway Management
Learning Curve
Keywords: I-gel
Protector
learning curve
LMA
airway
Lead sponsor: Sismanoglio General Hospital
Sponsor class: OTHER
First posted: 2025-04-22
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aims to compare the learning curves of two different laryngeal mask airway devices, by evaluating their placement in adult patients performed by anesthesiology residents


Eligibility criteria: Inclusion Criteria:

* ASA I-II
* Patients older than 18 years
* Procedures in supine and lithotomy position

Exclusion Criteria:

* Tumors or anatomical anomalies of the upper airway
* Known history of difficult intubation
* Limited mouth opening less than 2cm
* Decreased compliance of the lungs or the thoracic cage
* Need of mechanical ventilation after the surgery

Primary outcomes:
measure: The time required for successful placement of the device
timeFrame: Measured from the moment the clinician picks up the LMA device after induction of general anesthesia until the appearance of the first capnography waveform on the monitor with a maximum duration of 60 seconds per attempt and up to three attempts allowed
Secondary outcomes:
measure: Documentation of adverse events during placement
timeFrame: During the placement attempt
Other outcomes:
Locations:
city: Athens
country: Greece
facility: SismanoglioGH
state: Attiki
Study officials:
References:
Clinical trial NCT06881108: Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors
Official title: Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors: Efficacy and Implementation of a Multilevel Intervention in Community-Based Oncology Practices
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hematopoietic Neoplasm
Malignant Solid Neoplasm
Lymphatic System Neoplasm
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2025-03-18
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with perspectives on CHAT, LIFT, and FinFit's proposed forms as well as individuals from any community-based practice that were originally part of CHAT or LIFT administration

Brief summary: This study seeks to develop, test, and revise an intervention designed to address financial hardship (FinFit) among adolescent and young adult (AYA) cancer survivors.

Detailed description: PRIMARY OBJECTIVE:

I. To synthesize CHAT and LIFT to create FinFit, an intervention to address the unique, multilevel determinants of financial hardship among AYAs treated in community oncology practices.

OUTLINE: This is an observational study.

STEP 1: CHAT participants complete an in-depth interview on study.

STEP 2: LIFT participants complete a focus group or an interview on study.

STEP 3: Participants from steps 1 and 2 complete member-checking processes on study.

Eligibility criteria: Inclusion Criteria:

- Adults (ages 18 years of age or older) with perspectives on CHAT, LIFT, FinFit's proposed forms, and those from any community-based practices that were originally part of CHAT or LIFT administration are eligible for inclusion in Aim 1 interviews.

Exclusion Criteria:

- Those not involved in any of the preliminary programs, not familiar with the proposed forms of FinFit, or not involved in the proposed implementation sites will not be eligible for participation.

Primary outcomes:
measure: Combining Data Collection from Steps 1 and 2 for the Creation of FinFit Intervention Protocol
timeFrame: Up to 12 months
Secondary outcomes:
measure: CHAT Core Functions - Step 1
timeFrame: Up to 12 months
measure: LIFT Core Functions - Step 2
timeFrame: Up to 12 months
measure: Member Checking Process - Step 3
timeFrame: Up to 12 months
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest Baptist Comprehensive Cancer
state: North Carolina
Study officials:
affiliation: Wake Forest Baptist Comprehensive Cancer Center
name: John Salsman, PhD
role: PRINCIPAL_INVESTIGATOR
References: